Published reports and our previous studies have established that KPNA2 is highly expressed in multiple malignancies [2, 3, 8-17], and its alterations are often associated with an adverse outcome for breast carcinomas [9-11], esophageal cancer [12], lung cancer [13], prostate cancer [14], hepatocellular carcinoma [15], bladder cancer [16], brain cancer [17] and ovarian cancer [2, 3]. This evidence concerns the gene KPNA2 and prostate cancer.